DNAStar

The new distributor of DNAStar sequencing analysis software in Japan is a longtime partner of the Wisconsin software company.

The I-TASSER software is a multi-year winner of the Critical Assessment of Protein Structure Prediction challenge.

Enzymatics has launched version 3.0 of its Archer Analysis Pipeline. It's the latest incarnation of the company's next-generation sequence analysis platform for detecting and characterizing cancer-causing gene fusions and mutations from clinical samples.

CollabRx has launched CancerRx, a new oncology application that runs on Apple's operating system. The app provides oncologists and pathologists with treatment options that are based on their patients' tumors and also offers a daily newsfeed from MedPage Today.

NEW YORK (GenomeWeb) – DNAStar said this week that it has received a $150,000 Small Business Innovation Research grant from the National Institutes of Health's fast track award program to support the first phase of its efforts to improve and expand NovaFold, its cloud-based protein structure and

DNAStar said this week that the National Institute of Animal Biotechnology (NIAB) in Hyderabad, India, has licensed its Lasergene software for sequence assembly and analysis.

DNAStar said this week that Northwestern University has signed an agreement that will allow the company to provide its Lasergene software suite to all faculty, staff, and students at the institution.

DNAStar said this week that ShrimpEX Biotech Services, an Indian biotechnology company, has selected its Lasergene software for sequence assembly and analysis.

DNAStar said this week that the Wellcome Trust Sanger Institute has licensed its Lasergene software for primary sequence assembly and analysis.
The financial details of the arrangement were not disclosed.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.